X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES JUBILANT LIFE SCIENCES ALKEM LABORATORIES/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x - 16.8 - View Chart
P/BV x 7.1 4.4 161.8% View Chart
Dividend Yield % 0.6 0.4 147.3%  

Financials

 ALKEM LABORATORIES   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
JUBILANT LIFE SCIENCES
Mar-14
ALKEM LABORATORIES/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,589187 850.6%   
Low Rs1,23265 1,892.5%   
Sales per share (Unadj.) Rs417.5364.3 114.6%  
Earnings per share (Unadj.) Rs56.36.8 822.3%  
Cash flow per share (Unadj.) Rs64.724.5 264.1%  
Dividends per share (Unadj.) Rs12.703.00 423.3%  
Dividend yield (eoy) %0.92.4 37.8%  
Book value per share (Unadj.) Rs292.9164.9 177.6%  
Shares outstanding (eoy) m119.57159.28 75.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 977.4%   
Avg P/E ratio x25.118.4 136.2%  
P/CF ratio (eoy) x21.85.1 424.0%  
Price / Book Value ratio x4.80.8 630.4%  
Dividend payout %22.643.8 51.5%   
Avg Mkt Cap Rs m168,65320,061 840.7%   
No. of employees `000NA6.2 0.0%   
Total wages/salary Rs m9,17111,052 83.0%   
Avg. sales/employee Rs ThNM9,383.0-  
Avg. wages/employee Rs ThNM1,786.9-  
Avg. net profit/employee Rs ThNM176.3-  
INCOME DATA
Net Sales Rs m49,91558,034 86.0%  
Other income Rs m1,645191 863.1%   
Total revenues Rs m51,56158,224 88.6%   
Gross profit Rs m8,4825,786 146.6%  
Depreciation Rs m1,0062,812 35.8%   
Interest Rs m6713,237 20.7%   
Profit before tax Rs m8,451-72 -11,721.2%   
Minority Interest Rs m-114-286 39.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m1,606696 230.6%   
Profit after tax Rs m6,7311,090 617.3%  
Gross profit margin %17.010.0 170.4%  
Effective tax rate %19.0-965.9 -2.0%   
Net profit margin %13.51.9 717.7%  
BALANCE SHEET DATA
Current assets Rs m27,06229,280 92.4%   
Current liabilities Rs m15,32438,912 39.4%   
Net working cap to sales %23.5-16.6 -141.7%  
Current ratio x1.80.8 234.7%  
Inventory Days Days6784 78.8%  
Debtors Days Days4151 81.4%  
Net fixed assets Rs m12,61055,712 22.6%   
Share capital Rs m239155 154.8%   
"Free" reserves Rs m34,49020,968 164.5%   
Net worth Rs m35,02726,265 133.4%   
Long term debt Rs m1,21217,169 7.1%   
Total assets Rs m54,38788,606 61.4%  
Interest coverage x13.61.0 1,391.2%   
Debt to equity ratio x00.7 5.3%  
Sales to assets ratio x0.90.7 140.1%   
Return on assets %13.64.9 278.6%  
Return on equity %19.24.2 462.9%  
Return on capital %24.911.6 214.9%  
Exports to sales %12.937.8 34.2%   
Imports to sales %3.116.5 18.7%   
Exports (fob) Rs m6,46121,933 29.5%   
Imports (cif) Rs m1,5409,567 16.1%   
Fx inflow Rs m6,56322,004 29.8%   
Fx outflow Rs m3,01211,749 25.6%   
Net fx Rs m3,55210,255 34.6%   
CASH FLOW
From Operations Rs m7,2598,026 90.4%  
From Investments Rs m1,864-1,744 -106.9%  
From Financial Activity Rs m-9,273-4,447 208.5%  
Net Cashflow Rs m-1501,834 -8.2%  

Share Holding

Indian Promoters % 66.9 45.6 146.7%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 33.1 8.7 380.5%  
FIIs % 0.0 21.2 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 21.1 -  
Shareholders   68,381 23,815 287.1%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Aug 21, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS